nab-Paclitaxel + Gemcitabine

Metastatic pancreatic cancer (first-line): Standard of care in patients with ECOG PS 0–2. Metastatic breast cancer: nab-paclitaxel is FDA-approved as monotherapy; combination with gemcitabine used in clinical practice. NSCLC: nab-paclitaxel is FDA-approved in combination with carboplatin.

Pancreatic cancer (28-day cycle):
nab-Paclitaxel 125 mg/m² IV over 30–40 minutes on Days 1, 8, 15.
Gemcitabine 1000 mg/m² IV over 30 minutes on Days 1, 8, 15.
Repeat every 28 days. Dose reductions required for hematologic or other toxicity.

• Myelosuppression: Neutropenia is the primary dose-limiting toxicity. Monitor CBC before each weekly dose.
• Peripheral Neuropathy (nab-Paclitaxel): Sensory neuropathy in 17% grade 3+. Hold for Grade 3; resume at reduced dose when ≤Grade 1.
• Hypersensitivity (nab-Paclitaxel): Albumin-bound formulation reduces (but does not eliminate) hypersensitivity compared to solvent-based paclitaxel. Premedication generally not required.
• Pulmonary Toxicity (Gemcitabine): Severe pulmonary toxicity including interstitial pneumonitis. Discontinue if confirmed.
• Hepatotoxicity: AST/ALT elevations and hepatic failure reported with gemcitabine.
• Embryo-Fetal Toxicity: Both agents are teratogenic.

Neutropenia (73%), Nausea (54%), Fatigue (54%), Peripheral neuropathy (48%), Alopecia (50%), Anemia (50%), Diarrhea (30%), Thrombocytopenia (45%)

Adverse reaction frequencies reflect combination regimen data. Consult individual prescribing information for complete details.

This combination achieves synergistic cytotoxicity: nab-Paclitaxel (albumin-bound paclitaxel) stabilizes microtubules and inhibits depolymerization, causing mitotic arrest. The albumin-bound formulation improves tumor penetration via SPARC-mediated binding. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and is incorporated into DNA, terminating replication. nab-Paclitaxel also depletes cytidine deaminase (the enzyme that metabolizes gemcitabine), increasing gemcitabine exposure in tumors.

• MPACT — nab-Paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer. Phase III, n=861. Significant improvement in OS (8.5 vs 6.7 months, HR 0.72).
  🔬 NCT00844649 ↗📄 Primary Publication ↗